Owkin

United States
Troy, New Hampshire, United States, 10003

Company profile

Owkin company profile

Owkin is a French-American startup that uses artificial intelligence to find the right treatment for every patient. Our focus is to use AI to discover and develop better treatments for unmet medical needs, starting with the fight against cancer. They use AI to identify new drug candidates, de-risk and accelerate clinical trials and build diagnostic tools that improve patient outcomes. Using federated learning, a pioneering collaborative AI framework, Owkin enables medical and biopharma partners to unlock valuable insights from siloed datasets, while protecting patient privacy and securing proprietary data. Owkin was co-founded by Thomas Clozel MD, a clinical research doctor and former assistant professor in clinical onco-hematology, and Gilles Wainrib, a pioneer in the field of machine learning in biology, in 2016. Owkin has raised over $255 million and became a ‘unicorn’ – a startup valued at more than $1 billion – in November 2021 through a $180 million investment from French biopharma company Sanofi.

Business identity

Contact email
[email protected]
Phone number
(646) 398-9232
Operating status
Active
Company type
For Profit
Employee range
251-500 employees
Revenue range
$50,000+
Founded
2016-01-01, Year

Headquarters

Postal code
10003
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
Early Stage Venture
Funding rounds
8
Total equity funding
$304.1M
Last funding
Series B / $50M / 2022-06-08
Last equity funding
Series B / $50M
Investors
16
Lead investors
8
Founders
2
Articles
113

Founders and investors

Founders

Gilles WainribThomas Clozel

Lead investors

BpifranceBristol-Myers SquibbEight Roads VenturesF-PrimeGoogle VenturesMubadala Capital VenturesOtium CapitalSanofi

Investors

BpifranceCathay InnovationF-PrimePlug and PlaySanofi